GlassScriptPhysician profile
Slavisa Gasic
NPI 1558403337
$3,171.71
in general payments reported to CMS, 2019-2025
36 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,997 · 2020: $15.23 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,052 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,051.87 |
| Education | $107.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $575.99 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Pfizer INC. | $287.07 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $193.16 | 2019-2025 | |
| Astellas Pharma US INC | $188.97 | 2019-2025 | Vyloy |
| Incyte Corporation | $172.10 | 2019-2025 | Niktimvo, Jakafi |
| Merck Sharp & Dohme LLC | $143.41 | 2019-2025 | Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.77 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $134.76 | 2019 | |
| Abbvie INC. | $121.22 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $116.34 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.46 | 2019 | |
| Tesaro, INC. | $87.82 | 2019 | |
| Lilly USA, LLC | $73.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $71.10 | 2025 | Libtayo |
| Genzyme Corporation | $66.96 | 2019-2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $65.59 | 2019-2025 | Tecentriq, Venclexta |
| Eisai INC. | $60.87 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.27 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.97 | 2019 | |
| Exelixis INC. | $47.06 | 2019 | |
| Amgen INC. | $46.41 | 2019 | |
| Janssen Biotech, INC. | $43.35 | 2019-2025 | Darzalex, Tecvayli |
| Tersera Therapeutics LLC | $41.18 | 2019 | |
| Coherus Oncology, INC. | $30.84 | 2025 | Loqtorzi |
| Amag Pharmaceuticals, INC. | $28.29 | 2019 | |
| Daiichi Sankyo INC. | $26.78 | 2025 | Datroway |
| Seagen INC. | $25.57 | 2019 | |
| Stemline Therapeutics INC. | $25.15 | 2025 | Orserdu |
| Caris Mpi, INC. | $23.97 | 2025 | Mi Cancer Seek |
| Jazz Pharmaceuticals INC. | $21.19 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $20.69 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $18.95 | 2019 | |
| Verastem, INC. | $13.94 | 2019 | |
| Emd Serono, INC. | $13.48 | 2019 | |
| Gilead Sciences, INC. | $12.42 | 2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Slavisa Gasic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.